Literature DB >> 736591

Progressive interstitial lung disease from prolonged methotrexate therapy.

R L Kaplan, D H Waite.   

Abstract

Progressive interstitial fibrosis with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of methotrexate for 18 years. Examination revealed a combined restrictive and obstructive defect in pulmonary mechanics and severe compromise of gas transfer across the pulmonary alveolar-capillary membrane. Improvement in the level of arterial blood gases and pulmonary diffusing capacity occurred after discontinuation of methotrexate therapy. Interstitial fibrosis of the lung is a potential complication of methotrexate therapy for psoriasis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 736591

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  8 in total

Review 1.  A risk-benefit assessment of methotrexate in corticosteroid-dependent asthma.

Authors:  T R Shulimzon; R J Shiner
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

Review 2.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Systematic literature review investigating whether methotrexate causes chronic pulmonary fibrosis.

Authors:  Ed Quah; Constanta Amoasii; Tareg Mudawi; Julie Dawson
Journal:  Future Healthc J       Date:  2019-06

4.  Relationship of gold and penicillamine therapy to diffuse interstitial lung disease.

Authors:  D L Scott; G V Bradby; T J Aitman; G C Zaphiropoulos; C F Hawkins
Journal:  Ann Rheum Dis       Date:  1981-04       Impact factor: 19.103

Review 5.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

6.  Concomitant Interstitial Lung Disease with Psoriasis.

Authors:  Genta Ishikawa; Sakshi Dua; Aditi Mathur; Samuel O Acquah; Mary Salvatore; Mary B Beasley; Maria L Padilla
Journal:  Can Respir J       Date:  2019-08-25       Impact factor: 2.409

7.  Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review.

Authors:  Julie K Dawson; Edmond Quah; Ben Earnshaw; Constanta Amoasii; Tareg Mudawi; Lisa G Spencer
Journal:  Rheumatol Int       Date:  2021-01-29       Impact factor: 2.631

8.  Methotrexate and rheumatoid arthritis associated interstitial lung disease.

Authors:  Pierre-Antoine Juge; Joyce S Lee; Jessica Lau; Leticia Kawano-Dourado; Jorge Rojas Serrano; Marco Sebastiani; Gouri Koduri; Eric Matteson; Karina Bonfiglioli; Marcio Sawamura; Ronaldo Kairalla; Lorenzo Cavagna; Emanuele Bozzalla Cassione; Andreina Manfredi; Mayra Mejia; Pedro Rodríguez-Henriquez; Montserrat I González-Pérez; Ramcés Falfán-Valencia; Ivette Buendia-Roldán; Gloria Pérez-Rubio; Esther Ebstein; Steven Gazal; Raphaël Borie; Sébastien Ottaviani; Caroline Kannengiesser; Benoît Wallaert; Yurdagul Uzunhan; Hilario Nunes; Dominique Valeyre; Nathalie Saidenberg-Kermanac'h; Marie-Christophe Boissier; Lidwine Wemeau-Stervinou; René-Marc Flipo; Sylvain Marchand-Adam; Pascal Richette; Yannick Allanore; Claire Dromer; Marie-Elise Truchetet; Christophe Richez; Thierry Schaeverbeke; Huguette Lioté; Gabriel Thabut; Kevin D Deane; Joshua J Solomon; Tracy Doyle; Jay H Ryu; Ivan Rosas; V Michael Holers; Catherine Boileau; Marie-Pierre Debray; Raphaël Porcher; David A Schwartz; Robert Vassallo; Bruno Crestani; Philippe Dieudé
Journal:  Eur Respir J       Date:  2021-02-11       Impact factor: 33.795

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.